Literature DB >> 7744001

Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.

G Paonessa1, R Graziani, A De Serio, R Savino, L Ciapponi, A Lahm, A L Salvati, C Toniatti, G Ciliberto.   

Abstract

The helical cytokine interleukin (IL) 6 and its specific binding subunit IL-6R alpha form a 1:1 complex which, by promoting homodimerization of the signalling subunit gp130 on the surface of target cells, triggers intracellular responses. We expressed differently tagged forms of gp130 and used them in solution-phase binding assays to show that the soluble extracellular domains of gp130 undergo dimerization in the absence of membranes. In vitro receptor assembly reactions were also performed in the presence of two sets of IL-6 variants carrying amino acid substitutions in two distinct areas of the cytokine surface (site 2, comprising exposed residues in the A and C helices, and site 3, in the terminal part of the CD loop). The binding affinity to IL-6R alpha of these variants is normal but their biological activity is poor or absent. We demonstrate here that both the site 2 and site 3 IL-6 variants complexed with IL-6R alpha bind a single gp130 molecule but are unable to dimerize it, whereas the combined site 2/3 variants lose the ability to interact with gp130. The binding properties of these variants in vitro, and the result of using a neutralizing monoclonal antibody directed against site 3, lead to the conclusion that gp130 dimer is formed through direct binding at two independent and differently oriented sites on IL-6. Immunoprecipitation experiments further reveal that the fully assembled receptor complex is composed of two IL-6, two IL-6R alpha and two gp130 molecules. We propose here a model representing the IL-6 receptor complex as hexameric, which might be common to other helical cytokines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7744001      PMCID: PMC398293          DOI: 10.1002/j.1460-2075.1995.tb07186.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  34 in total

Review 1.  The hematopoietin receptor superfamily.

Authors:  D Cosman
Journal:  Cytokine       Date:  1993-03       Impact factor: 3.861

2.  Saturation mutagenesis of the human interleukin 6 receptor-binding site: implications for its three-dimensional structure.

Authors:  R Savino; A Lahm; M Giorgio; A Cabibbo; A Tramontano; G Ciliberto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

3.  Human soluble IL-6 receptor: its detection and enhanced release by HIV infection.

Authors:  M Honda; S Yamamoto; M Cheng; K Yasukawa; H Suzuki; T Saito; Y Osugi; T Tokunaga; T Kishimoto
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

4.  Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.

Authors:  A M de Vos; M Ultsch; A A Kossiakoff
Journal:  Science       Date:  1992-01-17       Impact factor: 47.728

5.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.

Authors:  N Stahl; T G Boulton; T Farruggella; N Y Ip; S Davis; B A Witthuhn; F W Quelle; O Silvennoinen; G Barbieri; S Pellegrini
Journal:  Science       Date:  1994-01-07       Impact factor: 47.728

6.  Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification.

Authors:  T Stoyan; U Michaelis; H Schooltink; M Van Dam; R Rudolph; P C Heinrich; S Rose-John
Journal:  Eur J Biochem       Date:  1993-08-15

7.  LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor.

Authors:  S Davis; T H Aldrich; N Stahl; L Pan; T Taga; T Kishimoto; N Y Ip; G D Yancopoulos
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

8.  Direct association of interleukin-6 with a 130-kDa component of the interleukin-6 receptor system.

Authors:  F D'Alessandro; O R Colamonici; R P Nordan
Journal:  J Biol Chem       Date:  1993-01-25       Impact factor: 5.157

9.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.

Authors:  M Murakami; M Hibi; N Nakagawa; T Nakagawa; K Yasukawa; K Yamanishi; T Taga; T Kishimoto
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

10.  Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130.

Authors:  H Yawata; K Yasukawa; S Natsuka; M Murakami; K Yamasaki; M Hibi; T Taga; T Kishimoto
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

View more
  42 in total

Review 1.  Receptor recognition by gp130 cytokines.

Authors:  J Bravo; J K Heath
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

2.  Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution.

Authors:  J G Zhang; C M Owczarek; L D Ward; G J Howlett; L J Fabri; B A Roberts; N A Nicola
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

3.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

Review 4.  Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance.

Authors:  Trupti D Vardam; Lei Zhou; Michelle M Appenheimer; Qing Chen; Wang-Chao Wang; Heinz Baumann; Sharon S Evans
Journal:  Cytokine       Date:  2007-07       Impact factor: 3.861

5.  Crystal structure of a cytokine-binding region of gp130.

Authors:  J Bravo; D Staunton; J K Heath; E Y Jones
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

Review 6.  Activating mechanism of CNTF and related cytokines.

Authors:  M Inoue; C Nakayama; H Noguchi
Journal:  Mol Neurobiol       Date:  1996-06       Impact factor: 5.590

7.  Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.

Authors:  Masahiko Hayashi; Mun-Chual Rho; Akiko Enomoto; Akiko Fukami; Yong-Pil Kim; Yuji Kikuchi; Toshiaki Sunazuka; Tomoyasu Hirose; Kanki Komiyama; Satoshi Omura
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

Review 8.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

9.  High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

Authors:  S Horiuchi; W Ampofo; Y Koyanagi; A Yamashita; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

10.  Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha- and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding.

Authors:  F C Stomski; Q Sun; C J Bagley; J Woodcock; G Goodall; R K Andrews; M C Berndt; A F Lopez
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.